Blood Reviews

Article	Citations
Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting	247
Interplay between platelets and coagulation	138
Targeting MCL-1 in hematologic malignancies: Rationale and progress	124
Coagulation and anticoagulation in COVID-19	121
Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system	116
Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes	106
The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis	94
Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: Potential role of antiplatelet agents	78
The looming storm: Blood and cytokines in COVID-19	62
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions	57
Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved	57
Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map	52
When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities	50
Coagulopathy and sepsis: Pathophysiology, clinical manifestations and treatment	49
A review of FLT3 inhibitors in acute myeloid leukemia	48
Role of inflammation in the biology of myeloproliferative neoplasms	48
Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions	45
COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research	45
Understanding terminal erythropoiesis: An update on chromatin condensation, enucleation, and reticulocyte maturation	42
Illness and prognostic understanding in patients with hematologic malignancies	41
Discussing investigational AAV gene therapy with hemophilia patients: A guide	38
Hematopoietic versus leukemic stem cell quiescence: Challenges and therapeutic opportunities	38
Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies	38
Inherited thrombocytopenias: an updated guide for clinicians	37
Current management strategies for polycythemia vera and essential thrombocythemia	35

Current and emerging strategies for management of myelodysplastic syndromes	33
Current state and next-generation CAR-T cells in multiple myeloma	33
Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer	31
Modern management of relapsed and refractory aggressive B-cell lymphoma: A perspective on the current treatment landscape and patient selection for CAR T-cell therapy	30
JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia	29
Second primary malignancies in multiple myeloma: A review	29
IKZF1 alterations in acute lymphoblastic leukemia: The good, the bad and the ugly	28
Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections	28
Targeting the gut microbiome: An emerging trend in hematopoietic stem cell transplantation	27
Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature	27
Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options	27
Thrombocytopenia in pregnancy: Diagnosis and approach to management	27
New developments in diagnosis, risk assessment and management in systemic amyloidosis	26
Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: Limitations of predictive models	24
CLL update 2022: A continuing evolution in care	24
Heterogeneity of congenital afibrinogenemia, from epidemiology to clinical consequences and management	22
The emerging role of red blood cells in cytokine signalling and modulating immune cells	22
The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma	22
Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways	22
Revving the CAR – Combination strategies to enhance CAR T cell effectiveness	22
Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies	22
Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?	22
Hormonal replacement therapy in adolescents and young women with chemo- or radio-induced premature ovarian insufficiency: Practical recommendations	21
Therapeutic strategies in low and high-risk MDS: What does the future have to offer?	21
Complement activation in COVID-19 and targeted therapeutic options: A scoping review	21
Use of molecularly-cloned haematopoietic growth factors in persons exposed to acute high-dose, high-dose rate whole-body ionizing radiations	20
Ex vivo expansion of hematopoietic stem cells: Finally transitioning from the lab to the clinic	20
Transfusion-related acute lung injury (TRALI): Potential pathways of development, strategies for prevention and treatment, and future research directions	20
Not all red cells sickle the same: Contributions of the reticulocyte to disease pathology in sickle cell anemia	20
Immune thrombocytopenia: A review of upfront treatment strategies	19
The critical roles of iron during the journey from fetus to adolescent: Developmental aspects of iron homeostasis	19
Older adults in hematologic malignancy trials: Representation, barriers to participation and strategies for addressing underrepresentation	19
A review on how to do hematology consults during COVID-19 pandemic	19
l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: Hype or hope?	19
Autoimmunity as a target for chimeric immune receptor therapy: A new vision to therapeutic potential	19
Optimising prophylaxis in haemophilia A: The ups and downs of treatment	18
The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag	18
Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations	18
Magnesium: The overlooked electrolyte in blood cancers?	18
A new era in oxygen therapeutics? From perfluorocarbon systems to haemoglobin-based oxygen carriers	18
Artificial intelligence in hematological diagnostics: Game changer or gadget?	18
It takes two to thrombosis: Hemolysis and complement	18
Revisiting Richter transformation in the era of novel CLL agents	17
Diagnosis of infectious diseases in immunocompromised hosts using metagenomic next generation sequencing-based diagnostics	17
Metabolic regulation of the bone marrow microenvironment in leukemia	17
AML and the art of remission maintenance	17
Management of challenging myelofibrosis after JAK inhibitor failure and/or progression	17
Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity	17
Hypereosinophilic syndromes – An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment	17
A new frontier in Fanconi anemia: From DNA repair to ribosome biogenesis	17

Hemophilia treatment in 2021: Choosing the”optimal” treatment using an integrative, patient-oriented approach to shared decision-making between patients and clinicians	17
The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation	16
Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option	16
The minimal that kills: Why defining and targeting measurable residual disease is the “Sine Qua Non” for further progress in management of acute myeloid leukemia	16
Peripheral neuropathy in hematologic malignancies – Past, present and future	16
Germline genetic factors in the pathogenesis of myeloproliferative neoplasms	15
Deciphering the messages carried by extracellular vesicles in hematological malignancies	15
Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap	15
PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias	14
Is microchimerism a sign of imminent disease recurrence after allogeneic hematopoietic stem cell transplantation? A systematic review of the literature	14
The extracellular matrix: A key player in the pathogenesis of hematologic malignancies	14
Arterial thrombosis in antiphospholipid syndrome (APS): Clinical approach and treatment. A systematic review	14
Loss of 5q in myeloid malignancies – A gain in understanding of biological and clinical consequences	14
The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia	14
A p53-JAK-STAT connection involved in myeloproliferative neoplasm pathogenesis and progression to secondary acute myeloid leukemia	14
Targeting health-related quality of life in patients with myelodysplastic syndromes – Current knowledge and lessons to be learned	14
Advances in the management of TTP	14
A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management	14
After 95 years, it's time to eRASe JMML	14
The diagnostic challenges of cardiac amyloidosis: A practical approach to the two main types	13
Unraveling survivin expression in chronic myeloid leukemia: Molecular interactions and clinical implications	13
Hematopoietic stem cell gene therapy: The optimal use of lentivirus and gene editing approaches	13
Fresh frozen plasma transfusion in the neonatal population: A systematic review	13
Past, present and future of prognostic scores in follicular lymphoma	13
The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses	13
Why do myeloma patients have bone disease? A historical perspective	12
Can we prevent or treat graft-versus-host disease with cellular-therapy?	12
BITES and CARS and checkpoints, oh my! Updates regarding immunotherapy for myeloid malignancies from the 2018 annual ASH meeting	12
Gut dysbiosis, endotoxemia and clotting activation: A dangerous trio for portal vein thrombosis in cirrhosis	12
Getting blood out of a stone: Identification and management of patients with poor hematopoietic cell mobilization	12
Decoding DNA methylation in epigenetics of multiple myeloma	11
Health related quality of life in children with sickle cell disease: A systematic review and meta-analysis	11
No apparent association between mRNA COVID-19 vaccination and venous thromboembolism	11
Current and future therapies for myelofibrosis	11
Serological biomarkers in hemophilic arthropathy: Can they be used to monitor bleeding and ongoing progression of blood-induced joint disease in patients with hemophilia?	11
Determinants of severity in sickle cell disease	10
A clandestine culprit with critical consequences: Benzene and acute myeloid leukemia	10
Maternal and neonatal bleeding complications in relation to peripartum management in hemophilia carriers: A systematic review	10
Prognostic models in the myeloproliferative neoplasms	10
Cardiovascular and haematological pathology in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): A role for viruses	10
Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives	10
The recipe for TACO: A narrative review on the pathophysiology and potential mitigation strategies of transfusion-associated circulatory overload	10
Free of malignancy but not of fears: A closer look at Damocles syndrome in survivors of hematologic malignancies	10
Genomic heterogeneity in myeloproliferative neoplasms and applications to clinical practice	10
Understanding the andromeda strain – The role of cytokine release, coagulopathy and antithrombin III in SARS-CoV2 critical illness	10
Promising role for mesenchymal stromal cells in coronavirus infectious disease-19 (COVID-19)-related severe acute respiratory syndrome?	10
Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting.	9
Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia	9
Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia	9
Assessing the risks of haemolysis as an adverse reaction following the transfusion of ABO incompatible plasma-containing components - A scoping review	9
Autonomic nervous system control of multiple myeloma	9
Follicular lymphoma: The long and winding road leading to your cure?	9
Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold?	9
Endothelial cells: major players in acute myeloid leukaemia	9
Insights on chronic immune thrombocytopenia pathogenesis: A bench to bedside update	9
Hemostatic changes by thrombopoietin-receptor agonists in immune thrombocytopenia patients	9
Complement in sickle cell disease and targeted therapy: I know one thing, that I know nothing	9
Neurologic complications of acute myeloid leukemia. Diagnostic approach and therapeutic modalities	8
Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation	8
Impact of transfusion on survival in patients with myelodysplastic syndromes: Current knowledge, new insights and transfusion clinical practice	8
Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers	8
Post-authorization pharmacovigilance for hemophilia in Europe and the USA: Independence and transparency are keys	8
Systematic review of staging bone marrow involvement in B cell lymphoma by flow cytometry	8
Tackling the unknowns in understanding and management of hospital acquired anemia	8
The future of research in hematology: Integration of conventional studies with real-world data and artificial intelligence	8
Infection profiles of different chemotherapy regimens and the clinical feasibility of antimicrobial prophylaxis in patients with DLBCL	8
Diagnosis and treatment of lymphomas in the era of epigenetics	7
Diffuse large B-cell lymphoma: Time to focus on circulating blood nucleic acids?	7
Challenging the concept of de novo acute myeloid leukemia: Environmental and occupational leukemogens hiding in our midst	7
Multipotent mesenchymal stromal cells in kidney transplant recipients: The next big thing?	7
Reality check: Real-world evidence to support therapeutic development in hematologic malignancies	7
Insight of fetal to adult hemoglobin switch: Genetic modulators and therapeutic targets	7
Clinical features and treatment strategies for post-transplant and iatrogenic immunodeficiency-associated lymphoproliferative disorders	7
Targeting cereblon in hematologic malignancies	7
Improving assessment and management of pain in hemophilia: an Italian Delphi consensus statement	7
Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies	7
Secondary antibody deficiency in chronic lymphocytic leukemia and non-Hodgkin lymphoma: Recommendations from an international expert panel	7
The evolving landscape of gene therapy for congenital haemophilia: An unprecedented, problematic but promising opportunity for worldwide clinical studies	7
Knowing the unknowns in high risk multiple myeloma	7
Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency	6

Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma	6
Follow-up issues in survivors of hematologic malignancies – Current stance and future perspectives	6
CHIPing away the progression potential of CHIP: A new reality in the making	6
Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs	6
Artificial intelligence in sickle disease	6
SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies	6
Back to base pairs: What is the genetic risk for red bloodcell alloimmunization?	6
The association between excess body weight at diagnosis and pediatric leukemia prognosis: A systematic review and meta-analysis	6
Allogeneic hematopoietic stem cell transplant for sickle cell disease: The why, who, and what	6
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium fo	6
T time: Emerging and new therapies for peripheral T-cell lymphoma	6